LAUSSANE, Switzerland—The Swiss company Sensimed has expanded its collaboration in Japan with SEED, a Japanese contact lens manufacturer.

According to a statement, the agreement enables the companies to combine efforts to work to obtain registration of the Sensimed Triggerfish, a non-invasive soft contact lens-based solution that is designed “to revolutionize glaucoma management by providing an automated recording of continuous ocular dimensional changes over 24 hours.”

The companies will work to conduct key pivotal clinical activities in Japan, and a 10 million Swiss franc financing deal will support registration in Japan and the work needed to “further validate unique diagnostic and predictive clinical claims for the technology,” the companies said. SEED contributed one-half of the funds, and current Sensimed investors matched this amount, the statement noted.

Sensimed Triggerfish is a platform technology that obtained a “first of a kind” FDA approval in March and which can be used to support alternative sensors focused on other clinical measurement applications, the companies said.

In its statement, Sensimed noted that it is also working toward validating the Triggerfish device “to actually predict the course of glaucoma so as to aid therapeutic choices,” and the company is seeking a strategic partner in the U.S. market to help achieve this goal.

“We are very pleased to expand our partnership with SEED, who have a solid organization to support the registration of our smart contact lens technology in Japan” Sensimed chief executive officer David Bailey said in the statement.